Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

Tomas Kauer - Moderator

Sep 8, 2024 - 02:00

Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

Tags:

Previous Article

Autopsy suggests tycoon Mike Lynch likely died of suffocation in yacht - source

Typhoon Yagi hits north Vietnam killing two and closing airports

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Tomas Kauer - Moderator

Related Posts

Paccurate helps companies ship in smaller boxes, saving them money while helping the earth

Paccurate helps companies ship in smaller boxes, saving...

Tomas Kauer - Mode... Oct 22, 2024

Futures waver on caution ahead of inflation report

Futures waver on caution ahead of inflation report

Tomas Kauer - Mode... Sep 10, 2024

Oyo founder seeks new investment at $3.8 billion valuation

Oyo founder seeks new investment at $3.8 billion valuation

Tomas Kauer - Mode... Nov 18, 2024